**Core tip:** This is a retrospective review to evaluate the association between postoperative pain control and oncologic outcomes in resected pancreatic ductal adenocarcinoma. In multivariate analysis, poor patients' perceived pain control was an independent risk factor for both disease-free survival (HR = 4.157; 95%CI: 1.938-8.915; *P* \< 0.001) and overall survival (HR = 4.741; 95%CI: 2.214-10.153; *P* \< 0.001) in resected left-sided pancreatic cancer. Adequate postoperative pain control to reduce patients' perceived pain during immediate postoperative period may be as important as adjuvant therapy in resected left-sided pancreatic cancer.

INTRODUCTION
============

Pancreas cancer is one of the most fatal malignancies in the world and is currently the fourth leading cause of cancer death in the United States\[[@B1]\]. Surgical excision remains the only curative therapy for pancreatic cancer. However, the resection rate is less than 20% at the time of initial diagnosis, and the rate of recurrence is extremely high even after surgery, occurring in up to 65% to 95% of patients\[[@B2]-[@B4]\]. To overcome the high incidence of micrometastatic disease, margin-negative resection\[[@B5]\] and the use of adjuvant treatment\[[@B2],[@B3],[@B6]\] have been considered as important prognostic factors of long-term survival. Nonetheless, 5-year overall survival remains less than 25% even after receiving adjuvant chemotherapy following resection\[[@B2],[@B3]\].

Recently, the importance of the perioperative period on oncologic outcome after cancer surgery has been emphasized in several review studies\[[@B7]-[@B10]\]. These studies underlined that the paracrine and neuroendocrine responses caused by surgical stress could promote tumor metastasis through direct action on residual malignant cells and by suppressing natural killer (NK) cell activity, thus compromising antimetastatic cell-mediated immunity (CMI)\[[@B8],[@B11],[@B12]\]. Downregulation of immunity after surgery is known to peak at postoperative day (POD) 3\[[@B13]\], and the decline in NK cell cytotoxicity has been documented to last until POD 7 to 9, depending on the surgical procedure\[[@B14]-[@B16]\]. A decrease in NK cell cytotoxicity following pancreaticoduodenectomy (PD) at POD 7 was also recently reported\[[@B17]\]. These results indicate that the early postoperative period harbors potential for the initiation of cancer metastasis, either *de novo* or from pre-existing micrometastasis.

Even when surgeons achieve R0 resection, various factors of this disproportionally pivotal perioperative period can facilitate growth of potential residual cancer beyond a critical immunological threshold, leading to cancer recurrence. Suggested perioperative risk factors that modulate surgery-induced immunosuppression include anesthetic technique, analgesic agents, blood transfusion, hypothermia, and pain\[[@B7]-[@B10]\].

Among these factors, acute pain is known to suppress NK cell activity\[[@B18]\], and its immunosuppressive properties have been shown to promote tumor growth in animal models\[[@B19]-[@B22]\]. Postsurgical pain activates the sympathetic nervous system (SNS), leading to catecholamine secretion\[[@B23]\], which directly inhibits NK cells. Furthermore, postoperative pain is not only a result of surgical tissue damage and nociception, but also reflects psychological stress, which has been reported as a risk factor of metastatic progression in some clinical trials\[[@B24],[@B25]\].

In spite of its potential role as an immunomodulator promoting tumor growth and metastasis, there has been no study to evaluate the oncologic significance of postoperative pain following resection of pancreas cancer. In this study, we investigated the association between postoperative pain control and oncologic outcomes in resected pancreatic ductal adenocarcinoma (PDAC).

MATERIALS AND METHODS
=====================

Patients and study design
-------------------------

From January 2009 to December 2014, 221 patients with PDAC underwent pancreatectomy with curative intent in our center. We retrospectively reviewed clinicopathologic characteristics and numerical rating scale (NRS) pain intensity score recorded in the nursing records system. One patient was excluded because of missing NRS data for an unknown reason and eight patients who required total pancreatectomy were also excluded (Figure [1](#F1){ref-type="fig"}). The study was reviewed and approved by the Institutional Review Board of Yonsei University College of Medicine.

![Patient eligibility. PDAC: Pancreatic ductal adenocarcinoma; NRS: Numerical rating scale; PD: Pancreaticoduodenectomy; PPPD: Pylorus-preserving pancreaticoduodenectomy; DP: Distal pancreatectomy with or without spleen preservation.](WJG-23-676-g001){#F1}

Data collection and analysis
----------------------------

NRS score from the nursing records system was available from 2009. Nurses administered the 11-point NRS, with the score ranging from 0 to 10, to evaluate pain intensity whenever the patients reported pain. Patients were instructed to rate 0 as "no pain at all"and 10 as "the worst possible pain". NRS scores during 7 postoperative days following resection of PDAC were reviewed.

We defined early pain score as the average of all pain scores reported on POD 1, 2, and 3 and late pain score as the average of scores reported on POD 5 and 7. In consideration of the subjective nature of pain and the importance of "perceived control", we applied the concept of pain control expressed as difference in pain intensity between the two periods rather than objective pain intensity value. We defined the "good pain control group" as the group of patients whose late pain intensity was lower than that of early pain intensity and the "poor pain control group" as the group of patients whose late pain intensity was the same or higher than the early pain intensity.

Postoperative complications were defined using the Clavien-Dindo classification of surgical complications\[[@B26]\]. Major complications were defined as complications with a Clavien-Dindo score of III or higher, which require additional interventional and/or medical treatment associated with prolonged hospital stay. TNM stages were classified according to the American Joint Committee on Cancer (AJCC; 7^th^ edition) staging system\[[@B27]\]. Multivisceral resection was defined as resection of any organ or a part of an organ other than the pancreas and spleen. Combined resection was defined as any multivisceral resection or vascular resection.

Statistical analysis
--------------------

Statistical analyses were performed using SPSS 20.0 for Windows (SPSS Inc., Chicago, IL, United States) and MedCalc 16.8.4 for Windows (MedCalc Inc., Mariakerke, Belgium). For continuous variables, *t*-test was performed and reported as mean and standard deviation. For matched data analysis, paired *t*-test was performed. Categorical variables were compared using the Chi-Square test or Fisher's exact test and reported as number (*n*) and percentage (%). Overall survival (OS) rates and disease-free survival (DFS) rates were estimated using the Kaplan-Meier method. Log-rank test was performed to compare the categorical groups in univariate analysis. A multivariable Cox proportional hazards regression model was used to determine independent risk factors associated with OS and DFS. This model included all of the categorized patient, resection, and tumor characteristics with log-rank *P* values ≤ 0.150. Exponential (β) measures were reported with 95%CI to evaluate the risks associated with each factor. Statistical significance was achieved at *P* \< 0.05.

RESULTS
=======

Patients characteristics
------------------------

A total of 212 patients who underwent pancreatectomy for PDAC were retrospectively reviewed. The clinicopathological characteristics are summarized in Table [1](#T1){ref-type="table"}. Median follow-up period was 17 mo. Sixty-six patients (31.3%) received neoadjuvant concurrent chemoradiotherapy (CCRT) before pancreas resection, and 154 patients (72.6%) received adjuvant treatment of chemotherapy, radiotherapy, or CCRT according to their general condition. R0 resection was achieved in 187 patients (88.2%). In terms of resection methods, 146 patients (68.9%) underwent pancreaticoduodenectomy (PD) or pylorus-preserving pancreatoduodenectomy (PPPD), and 66 patients (31.1%) underwent distal pancreatectomy (DP) with or without spleen preservation.

###### 

Clinicopathologic characteristics of the patients *n* (%)

  **Characteristic (*n* = 212)**   **Frequency, mean ± SD**
  -------------------------------- --------------------------
  Age (yr)                         62.8 ± 9.5
  Male gender                      125 (59.0)
  BMI (kg/m^2^)                    22.8 ± 2.9
  Diabetes                         73 (34.4)
  ASA                              
  1                                66 (31.1)
  2                                92 (43.4)
  3                                49 (23.1)
  4                                2 (0.9)
  Operative time (min)             402.2 ± 129.3
  Intraoperative bleeding (mL)     626.0 ± 482.8
  Intraoperative transfusion       47 (22.2)
  pT stage                         
  T0                               9 (4.2)
  T1                               16 (7.5)
  T2                               3 (1.4)
  T3                               182 (85.8)
  T4                               2 (0.9)
  pN stage                         
  N0                               106 (50.0)
  N1                               106 (50.0)
  pTNM staging                     
  I                                18 (8.5)
  II                               182 (85.8)
  III                              2 (0.9)
  IV                               1 (0.5)
  R status                         
  R0                               187 (88.2)
  R1                               23 (10.8)
  R2                               2 (0.9)
  Cell differentiation             
  Well                             24 (11.3)
  Moderate                         152 (71.7)
  Poor                             17 (8.0)
  Undifferentiated                 1 (0.5)
  Retrieved lymph nodes            17.3 ± 9.9
  Vascular resection               55 (25.9)
  Mutivisceral resection           36 (17.5)
  Combined resection               71 (33.5)
  Lymphovascular invasion          71 (33.5)
  Perineural invasion              146 (68.9)
  Neoadjuvant CCRT                 66 (31.3)
  Adjuvant treatment               154 (72.6)
  Complications                    
  Minor                            112 (52.8)
  Major(≥ G3)                      20 (9.4)
  Length of hospital stay (d)      21.1 ± 15.0
  Recurrence                       137 (64.6)

ASA: American Society of Anesthesiologists; CCRT: Concurrent chemoradiotherapy.

Changes in postoperative pain intensity following pancreatectomy
----------------------------------------------------------------

For the overall patient population, postoperative pain intensity decreased significantly at POD 2, 3, 5, and 7 compared with POD 1 (*P* \< 0.001 for each; Figure [2](#F2){ref-type="fig"}). There was a significant decrease in pain intensity between each two successive days (*P* \< 0.001), except between POD 2 and 3 (*P* = 0.916).

![Overall changes in postoperative numerical rating scale pain intensity following pancreatectomy. POD: Postoperative day; NRS: Numerical rating scale.](WJG-23-676-g002){#F2}

Patients were divided into a good pain control group (*n* = 162) and poor pain control group (*n* = 50). The good pain control group showed a reduction of pain intensity from 4.13 ± 0.93 to 2.87 ± 0.86 for the PD group (*n* = 109, *P* \< 0.001) and from 3.71 ± 0.77 to 2.69 ± 0.78 for the DP group (*n* = 53, *P* \< 0.001, Figure [3A](#F3){ref-type="fig"}). The poor pain control group showed an increase of pain intensity from 3.35 ± 0.87 to 4.03 ± 1.02 for the PD group (*n* = 37, *P* \< 0.001) and from 2.71 ± 0.99 to 3.26 ± 0.88 for the DP group (*n* = 13, *P* = 0.003, Figure [3B](#F3){ref-type="fig"}).

![Change in numerical rating scale pain intensity following pancreatectomy stratified by quality of pain control. A: Good pain control group (*n* = 109, PD; *n* = 53, DP); B: Poor pain control group (*n* = 37, PD; *n* = 13, DP). PD: Patients underwent pancreaticoduodenectomy or pylorus-preserving pancreaticoduodenectomy; DP: Patients underwent distal pancreatectomy; POD: Postoperative day; NRS: Numerical rating scale.](WJG-23-676-g003){#F3}

Oncologic impact of postoperative pain intensity following pancreatectomy
-------------------------------------------------------------------------

A negative impact of poor postoperative pain control on OS was observed in the DP group \[good pain control *vs* poor pain control, median survival 42.0 mo (95%CI: 26.2-57.8) *vs* 15.0 mo (95%CI: 11.5-18.5), *P* = 0.001, Figure [4B](#F4){ref-type="fig"}\]. Also, poor pain control exerted a negative effect on DFS in the DP group (good pain control *vs* poor pain control, median 18.0 mo *vs* 8.0 mo, *P* = 0.001, Figure [4D](#F4){ref-type="fig"}). Patients undergoing pancreaticoduodenectomy or pylorus-preserving pancreaticoduodenectomy (PD group) did not show associations between postoperative pain control and oncologic outcomes.

![Oncologic outcomes. Comparison of overall survival between the good pain control group (solid line) and poor pain control group (dotted curve) after pancreaticoduodenectomy (PD) (A) and distal pancreatectomy (DP) (B); Comparison of disease-free survival between the good pain control group (solid line) and poor pain control group (dotted curve) after PD (C) and DP (D).](WJG-23-676-g004){#F4}

Comparison between the good pain control group and the poor pain control group among patients undergoing distal pancreatectomy
------------------------------------------------------------------------------------------------------------------------------

There were no significant differences in preoperative, intraoperative, or postoperative outcomes between the good pain control group and the poor pain control group (*P* \> 0.05, Table [2](#T2){ref-type="table"}). Other interesting finding was that surgical approach, such as open or minimally invasive, did not influence categorization of pain response (*P* = 0.523). Whether the patients received neoadjuvant CCRT or not also did not affect grouping of pain control (*P* = 0.719). There were also no differences in method of postoperative pain management techniques between the group (*P* = 0.445).

###### 

Clinicopathologic differences between the good pain control group and poor pain control group undergoing distal pancreatectomy *n* (%)

                                   **Pain control group**   ***P* value**    
  -------------------------------- ------------------------ ---------------- ----------
  Age (yr)                         65.6 ± 8.2               63.2 ± 11.3      0.378
  Male gender                      30 (56.6)                7 (53.8)         0.858
  BMI (kg/m^2^)                    23.1 ± 2.7               23.1 ± 2.4       0.993
  Diabetes                         17 (32.1)                3 (23.1)         0.739
  ASA                                                                        
  1                                16 (30.2)                5 (41.7)         0.342
  2                                22 (41.5)                6 (50.0)         
  3                                15 (28.3)                1 (8.3)          
  Surgical approach                                                          
  Open                             35 (66.0)                7 (53.8)         0.523
  MIS                              18 (34.0%)               6 (46.2)         
  Spleen preservation              7 (13.2)                 2 (15.4)         \> 0.999
  Operation time (min)             254.1 ± 95.3             304.6 ± 89.0     0.088
  Intraoperative bleeding (mL)     364.2 ± 296.0            470.38 ± 624.8   0.373
  Intraoperative transfusion       5 (9.4)                  3 (23.1)         0.185
  Tumor size (cm)                                                            0.407
  \< 3                             30 (56.6)                9 (69.2)         
  ≥ 3                              23 (43.4)                4 (30.8)         
  pT stage                                                                   0.148
  T0                               3 (5.7)                  0 (0)            
  T1                               3 (5.7)                  2 (15.4)         
  T2                               2 (3.8)                  1 (7.7)          
  T3                               45 (84.9)                9 (69.2)         
  T4                               0 (0.0)                  1 (7.7)          
  pN stage                                                                   0.851
  N0                               27 (50.9)                7 (53.8)         
  N1                               26 (49.1)                6 (46.2)         
  pTNM staging                                                               0.429
  I                                5 (9.5)                  2 (15.4)         
  II                               44 (83.0)                10 (77.0)        
  III                              0 (0.0)                  1 (7.7)          
  IV                               1 (1.9)                  0 (0.0)          
  R status                                                                   0.121
  R0                               47 (88.7)                11 (84.6)        
  R1                               6 (11.3 )                1 (7.7)          
  R2                               0 (0.0 )                 1 (7.7)          
  Retrieved lymph nodes            14.8 ± 11.0              14.2 ± 6.6       0.735
  Multivisceral resection          12 (22.6)                2 (15.4)         0.718
  Combined resection               14 (26.4)                2 (15.4)         0.496
  Lymphovascular invasion          14 (27.5)                4 (33.3)         0.729
  Perineural invasion              34 (66.7)                5 (41.7)         0.185
  Grade                                                                      0.499
  Well                             3 (6.4)                  2 (16.7)         
  Moderate                         38 (80.9)                9 (75.0)         
  Poor                             6 (12.8)                 1 (8.3)          
  Neoadjuvant CCRT                 12 (22.6)                4 (30.8)         0.719
  Preoperative CA19-9                                                        0.154
  \< 300                           34 (69.4)                12 (92.3)        
  ≥ 300                            15 (30.6)                1 (7.7)          
  Adjuvant treatment               39 (73.6)                9 (69.2)         0.739
  Time to adjuvant treatment (d)   53.7 ± 36.8              63.0 ± 47.0      0.520
  Complications                                                              
  Minor                            33 (62.3)                7 (53.8)         0.578
  Major(≥ G3)                      3 (7.3)                  2 (28.6)         0.148
  Use of PCA                                                                 0.445
  IV PCA                           34 (64.2)                10 (76.9)        
  Epidural PCA                     17 (32.1)                2 (15.4)         
  None                             2 (3.8)                  1 (7.7)          
  Length of hospital stay (d)      17.1 ± 11.0              27.2 ± 45.9      0.446

ASA: American Society of Anesthesiologists; CCRT: Concurrent chemoradiotherapy; MIS: Minimal invasive surgery; PCA: Patient-controlled analgesia.

Independent prognostic factors in resected left-sided pancreatic cancer
-----------------------------------------------------------------------

In univariate analysis, intraoperative transfusion, positive lymph node status, greater tumor diameter (≥ 3 cm), and poor pain control were identified as prognostic factors for predicting DFS in resected left-sided pancreatic cancer (*P* = 0.005, *P* = 0.011, *P* = 0.028, *P* = 0.001, respectively; Table [3](#T3){ref-type="table"}). For OS, longer operation time (≥ 300 min), positive lymph node status, greater tumor diameter (≥ 3 cm), multivisceral resection, not receiving adjuvant treatment, and poor pain control were significant prognostic factors in univariate analysis (*P* = 0.035, *P* = 0.020, *P* = 0.023, *P* = 0.043, *P* = 0.017, *P* = 0.001, respectively; Table [3](#T3){ref-type="table"}). Subsequent multivariate analysis revealed positive lymph node status, greater tumor diameter (≥ 3 cm), not receiving adjuvant treatment, and poor pain control as independent risk factors for both DFS and OS in resected left-sided pancreatic cancer (Table [4](#T4){ref-type="table"}).

###### 

Univariate analysis of factors affecting disease-free survival and overall survival after distal pancreatectomy

                               ***n***   **DFS**   **OS**        
  ---------------------------- --------- --------- -------- ---- -------
  Age                                                            
  \< 65                        30        15        0.216    42   0.150
  ≥ 65                         36        11                 23   
  Sex                                                            
  Female                       29        11        0.136    27   0.829
  Male                         37        18                 33   
  BMI (kg/m^2^)                                                  
  \< 25                        52        11        0.209    30   0.384
  ≥ 25                         14                           27   
  Diabetes                                                       
  No                           46        13        0.674    27   0.654
  Yes                          20        15                      
  ASA                                                            
  1/2                          49        13        0.569    30   0.903
  3/4                          16        15                      
  Surgical approach                                              
  Open                         42        14        0.971    30   0.645
  MIS                          24        11                 41   
  Spleen preservation                                            
  Yes                          9         15        0.931    27   0.619
  No                           57        13                 33   
  Operation time (min)                                           
  \< 300                       39        17        0.254    41   0.035
  ≥ 300                        27        13                 15   
  Bleeding (mL)                                                  
  \< 500                       42        11        0.632    30   0.881
  ≥ 500                        23        15                 33   
  Intraoperative transfusion                                     
  No                           58        15        0.005    33   0.056
  Yes                          8         4                  13   
  Resection status                                               
  R0                           58        13        0.689    30   0.382
  R1/R2                        8         13                 21   
  Lymph node status                                              
  N0                           34                  0.011    41   0.020
  N1                           32        9                  17   
  Tumor size (cm)                                                
  \< 3                         39        18        0.028    42   0.023
  ≥ 3                          27        8                  15   
  pT stage                                                       
  ≤ 2                          11                  0.293    21   0.949
  ≥ 3                          55        13                 33   
  Multivisceral resection                                        
  No                           52        15        0.111    33   0.043
  Yes                          14        10                 13   
  Combined resection                                             
  No                           50        15        0.474    33   0.303
  Yes                          16        10                 15   
  Lymphovascular invasion                                        
  No                           45        11        0.259    23   0.762
  Yes                          18        18                 30   
  Perineural invasion                                            
  No                           24        11        0.947    21   0.621
  Yes                          39        15                 27   
  Neoadjuvant CCRT                                               
  Yes                          16        15        0.351    33   0.433
  No                           50        11                 21   
  Preop CA19-9 (U/mL)                                            
  \< 300                       46        15        0.782    27   0.540
  ≥ 300                        16        13                 42   
  Adjuvant treatment                                             
  Yes                          48        15        0.094    41   0.017
  No                           18        4                  8    
  Major complications (≥ G3)                                     
  No                           43        15        0.813    42   0.916
  Yes                          5         4                  21   
  Use of PCA                                                     
  Epidural                     19        13        0.757    27   0.943
  IV                           44        15                 33   
  Pain control                                                   
  Good                         53        18        0.001    42   0.001
  Poor                         13        8                  15   

*P* values were obtained using a log-rank test. DFS: Disease-free survival; OS: Overall survival; ASA: American Society of Anesthesiologists; MIS: Minimal invasive surgery; CCRT: Concurrent chemoradiotherapy; PCA: Patient-controlled analgesia.

###### 

Univariate and multivariate Cox regression analysis of factors affecting disease-free survival and overall survival after distal pancreatectomy

  **Variables**                **Disease-free survival**   **Overall survival**                                                                                                 
  ---------------------------- --------------------------- ---------------------- ------- ------- ------------- ---------- ------- ------------- ------- ------- -------------- ----------
  Positive lymph node status   2.183                       1.162-4.101            0.011   2.259   1.150-4.437   0.018      2.105   1.094-4.053   0.02    2.501   1.218-5.134    0.012
  Tumor size (≥ 3 cm)          1.943                       0.999-3.781            0.028   2.215   1.130-4.341   0.021      2.030   1.016-4.055   0.023   2.662   1.282-5.529    0.009
  No adjuvant treatment        1.742                       0.800-3.794            0.094   2.468   1.196-5.093   0.015      2.205   0.981-4.955   0.017   4.649   2.124-10.172   \< 0.001
  Poor pain control            2.934                       1.158-7.430            0.001   4.157   1.938-8.915   \< 0.001   2.915   1.156-7.350   0.001   4.741   2.214-10.153   \< 0.001
  Age (≥ 65 yr)                ND                                                         ND                               1.608   0.844-3.064   0.150   1.706   0.799-3.640    0.167
  Sex (Male)                   0.632                       0.338-1.181            0.136   0.614   0.318-1.186   0.146      ND                            ND                     
  Operation time (≥ 300 min)   ND                                                         ND                               1.949   0.981-3.873   0.035   1.890   0.923-3.868    0.082
  Intraoperative transfusion   2.788                       0.903-8.612            0.005   1.745   0.688-4.425   0.241      2.159   0.729-6.396   0.056   1.986   0.750-5.257    0.167
  Multivisceral resection      1.720                       0.769-3.849            0.111   1.166   0.532-2.557   0.701      2.046   0.837-5.006   0.043   1.273   0.563-2.876    0.562

ND: Not determined due to lack of significance.

DISCUSSION
==========

Evidence showing the association of pain relief and reduced surgery-induced tumor growth was first documented by Yeager et al\[[@B28]\] in colon carcinoma. Since then, the protective effect of various analgesics on surgery-induced metastasis has been reported by many studies\[[@B19],[@B20],[@B29]-[@B31]\]. However, there has been no study to evaluate the oncologic significance of postoperative pain control following resection of pancreatic cancer. To the best of our knowledge, the current retrospective study is the first to suggest that early postoperative pain control can influence patient survival after DP for PDAC, regardless of the biology of the tumor, surgical approach, or treatment modality.

A possible mechanism explaining the association of poor pain control and negative oncologic outcome could include interaction of inflammation, pain, and suppressed NK cell activity in the early postsurgical period, resulting in immunosuppression, which is known to peak on POD 3. The immunosuppressive property of pain is attributed to the direct inhibition of NK cell cytotoxicity by catecholamine secreted upon SNS activation\[[@B11],[@B12]\]. Also, postoperative pain is associated with increased secretion of proinflammatory cytokines such as interleukin (IL)-1β, IL-6, and tumor necrosis factor (TNF)-α. Sommer et al\[[@B32]\] indicated that pain and proinflammatory cytokines interact reciprocally. Pain affects the production and secretion of cytokines, and those cytokines reduce the activation threshold of peripheral nociceptors, resulting in pain augmentation. Several studies\[[@B33]-[@B35]\] have shown the association of pain relief in the immediate postoperative period and attenuated production of proinflammatory cytokines. The correlation between changes in proinflammatory cytokine levels and decreased NK cell response was also reported by Baxevanis et al\[[@B15]\]. Considering these findings, unrelieved or elevated pain intensity at the late postsurgical period (POD 5, 7) might reflect prolonged inflammation and a state of immunosuppression and thus a higher chance of tumor metastasis and recurrence, explaining the negative oncologic outcome.

Poor pain control is basically attributed to a failure of appropriate and adequate postoperative analgesic care. However, it has also been suggested that poor pain response can be a result of the patient-specific immune state before surgery\[[@B36]\], a sign of ongoing or forthcoming complications\[[@B37],[@B38]\], or a contributory effect of perioperative psychological factors\[[@B39],[@B40]\]. Since there were no significant differences in any clinicopathologic factors between the good pain control group and poor pain control group undergoing DP (Table [2](#T2){ref-type="table"}), we can only speculate that inadequate postoperative pain control was the major reason for poor postoperative pain control in left-sided pancreatic cancer. Further study should include establishment of appropriate pain control protocol to minimize influence of inadequate pain control and evaluate whether there are other possible reasons for poor postoperative pain control in left-sided pancreatic cancer.

Currently, it is routine for patients undergoing pancreas cancer surgery to receive adjuvant treatment irrespective of whether R0 resection is achieved. Therefore, the postsurgical period has been viewed as a time for managing complications and improving the general condition of the patient in order to meet the physiological requirements for receiving adjuvant treatment. During this approximately two-months period, patients do not receive anticancer treatment or intervention. However, this period - especially the immediate early period - harbors a therapeutic window of anticancer treatment, as surgery-induced immunosuppression is still in its recovery phase, and the tumor burden could start to increase again. Although, present study is based on a small sample size and retrospective observation, our data suggest that pain management after DP could be more than a matter of patient recovery to receive adjuvant treatment at the appropriate time. Rather, adequate and appropriate pain control during the early postoperative period might exert a direct curative effect on left-sided pancreatic cancer.

Interestingly, the negative oncologic impact of postoperative pain control was not observed following PD. This may have been influenced by wider surgical extent involved with PD and the impact of postoperative pain control during the postoperative 7 days may be rendered ineffective. The operation time, intraoperative blood loss, and rate of intraoperative transfusion were all higher after PD compared to DP \[448.3 min *vs* 264.1 min, *P* \< 0.001; 717.9 cc *vs* 385.5 cc, *P* \< 0.001; 39 (26.9%) *vs* 8 (12.1%), *P* = 0.017, respectively, data not shown\], reflecting greater surgical stress. Increased surgical extent has been shown to be associated with higher rates of tumor metastasis\[[@B41]\] and delayed recovery of NK cell cytotoxicity\[[@B15]\]. Also, intraoperative transfusion has been repeatedly reported to modulate the postoperative immune response\[[@B42],[@B43]\]. These factors may overcome the potential immune modulation and oncologic effect of pain control during the period of assessment.

Our study has several limitations. It is a retrospective study, and the number of patients in the poor pain control group after DP was small, making it difficult to reach sound conclusions. We grouped patients into good and poor pain control groups according to differences in NRS pain intensity between early (POD 1, 2, 3) and late (POD 5, 7) periods, because inflammation and immunosuppression peak on around POD 3. However, this time frame might not fit all cases and may vary according to surgical extent or approach. Future studies are needed to test various analytic approaches targeting the critical time point when postoperative pain most significantly mediates immunomodulation.

In addition, our definition of pain control groups may not fully represent pain control state. There have been reports of using satisfaction score along with pain score in fully assessing adequate pain control\[[@B44],[@B45]\]. In determining pain control state, we were limited to the use of NRS pain intensity. Further studies with assessment of satisfaction score and refined definitions for pain control groups should be undertaken.

Lastly, for pain control, patients received intravenous patient-controlled analgesia (PCA) or epidural PCA (both based on fentanyl) or opiates on demand. However, disconnect timing of PCA, as well as the type and amount of analgesics used after clamping, were not investigated in this study. Opioids are believed to exert an immunosuppressive effect when they are used in the absence of pain\[[@B22]\]. Also, certain types of opioids, such as tramadol (but not all opioids) can overcome the immunosuppressive effects of pain, reversing the capacity of surgical stress to suppress NK cell cytotoxicity and promote tumor metastasis in animal models\[[@B20],[@B46]\]. The complex interaction of pain, opioids, non-opioid analgesics, and their net effect on immunosuppression, which might have impacted oncologic outcome, was not assessed in this study. However, relationship between pain control method and postoperative pain control should be investigated further with a well-designed pain control protocol.

This study suggests that a change in patients' perceived pain intensity in the postoperative period could influence survival outcome in resected left-sided pancreatic cancer. Unlike other prognostic factors, such as tumor size, lymph node metastasis, differentiation, lymphovascular invasion, and perineural invasion, postoperative pain is a controllable factor. Surgeons play a leading role in controlling pain during the postoperative period. In spite of compelling evidence supporting the immunologic and oncologic importance of the perioperative period, its application to the clinical field is still in its infancy. More research on underutilized modulators of this period - not only postoperative pain, but also intraoperative hypothermia, transfusion, nutritional support, and psychological intervention - is needed for the development of patient-oriented perioperative therapy against pancreatic cancer.

In conclusion, adequate postoperative pain relief during the early postoperative period has important clinical implications for oncologic outcomes after resection of left-sided pancreatic cancer.

COMMENTS
========

Background
----------

Acute pain is known to suppress natural killer (NK) cell cytotoxicity and promote tumor growth and metastasis in preclinical models. Therefore, postoperative pain has been suggested as one of the risk factors for cancer metastasis and recurrence after oncologic surgery. Surgery-induced immunosuppression and inflammation are known to peak around postoperative day (POD) 3, and suppression of NK cell cytotoxicity lasts from approximately POD 7 to 9. The clinical significance of postoperative pain control during this critical period in patients undergoing pancreatectomy for pancreatic ductal adenocarcinoma (PDAC) has yet to be investigated.

Research frontiers
------------------

This study contributes in discovering associations between postoperative pain control and oncologic outcomes in resected pancreatic cancer.

Innovations and breakthroughs
-----------------------------

In this study, patients undergoing distal pancreatectomy for left-sided pancreatic cancer were found to have poor oncologic outcomes under poor postoperative pain control. Adequate postoperative pain relief during the early postoperative period has important clinical implications for oncologic outcomes after resection of left-sided pancreatic cancer.

Applications
------------

Surgeons play a leading role in controlling pain during the postoperative period. Patients' perceived postoperative pain should be actively relieved after distal pancreatectomy for pancreatic cancer to improve oncologic outcomes.

Terminology
-----------

PD group: Patients underwent pancreaticoduodenectomy or pylorus-preserving pancreaticoduodenectomy. DP group: Patients underwent distal pancreatectomy. Good pain control group: Patients whose late pain intensity was lower than that of early pain intensity. Poor pain control group: Patients whose late pain intensity was the same or higher than the early pain intensity. Early pain intensity: Mean of all pain scores reported on POD 1, 2, and 3. Late pain intensity: Mean of pain scores reported on POD 5 and 7. Pain scores: Measurement of numerical rating scale (NRS) pain intensity score. 11-point NRS with the score ranging from 0 to 10 was used to evaluate pain intensity whenever the patients reported pain. Patients were instructed to rate 0 as "no pain at all" and 10 as "the worst possible pain".

Peer-review
-----------

The study evaluated the association between postoperative pain control and oncologic outcomes in resected PDAC. The results showed that poor pain control was an independent risk factor for both DFS and OS in resected left-sided pancreatic cancer, but not in patients received PD. This is very interesting.
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